Novel diagnostic method for breast cancer and ovarian cancer
About 5-10 % of all breast cancers are hereditary, and in 30-40% of these cases a mutation in the BRCA1/2 genes can be detected. The tumor biology of carcinomas with BRCA1 mutation differs significantly from sporadic cancers and cases with BRCA2 mutations involved. It is known that in breast cancer tissue shows a significantly higher T3 receptor (Trijodothyronin receptor, THR) binding capacity as compared to normal breast tissue.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Recovering phosphorus from sewage sludge ash
Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…
Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids
EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…
After 25 years, researchers uncover genetic cause of rare neurological disease
Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…
